Emily Kobayashi (Head of HPV Program, Gavi) and regional EPI managers (Guinea, Malawi, Cameroon, DRC) addressed the operationalization of the Gavi 6.0 model at the 2025 CHIC Symposium. The session clarified that the new unified grant integrates Gavi resources with national budgets and partner funding (e.g., World Bank). Key concerns focused on the 4% co-financing […]
Format: Q&A Session
Financial and/or sustainability in the context of expanding target population for vaccination – Q&A
Discussion addressed the differentiated pricing landscape for HPV vaccines, clarifying that GAVI-eligible countries may access GAVI prices even for expanded target groups and that UNICEF procurement functions as an indirect pool procurement mechanism benefiting countries with small purchasing volumes. On the economics of local manufacturing, Bloem acknowledged the 10-year timeline and higher per-dose costs typical […]
Articulating the challenges: Country experiences improving service delivery through a lens of persistent challenges – Q&A
This Q&A session followed country presentations from The Gambia, Senegal, and Zimbabwe on HPV service delivery challenges, drawing responses from Kenya and Rwanda as well. The Gambia clarified that its 2024 vaccine stockout stemmed from post-COVID hesitancy causing demand shortfalls during a campaign, leading to expiry rather than supply failure. Senegal explained that district-level financing […]
Resource Mobilization and Financial Sustainability: Q&A Session
This Q&A addressed private sector engagement, civil society advocacy across government transitions, Kenya’s Gavi re-entry, and South Africa’s Mother-Daughter campaign. Zimbabwe framed HPV as a community protection investment to attract private sector support; Kenya confirmed a 2028 target for first Kenya BioVax doses. Kenya’s return to the Gavi preparatory phase followed a GNI threshold review […]
Challenges and good practices for sustaining delivery after a MAC introduction: Nigeria’s experience towards cervical cancer elimination – Q&A Session
This Q&A followed Nigeria’s presentation on sustaining delivery after MAC introduction, with exchanges drawing parallels from the DRC, which introduced HPV vaccination in 2024 and identified similar phase-specific challenges. Nigeria clarified that the large total figure of girls reached combines MAC campaign outcomes (over 12.3 million) with routine and targeted intensification efforts (approximately 2.9 million), […]
Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Q&A Session
This Q&A session addressed questions on vaccine procurement sustainability, local manufacturing rationale, and the cost-competitiveness of HPV vaccines relative to other antigens. On procurement capacity, Kenya’s representative noted that disruptions caused by the withdrawal of US government funding for data management activities underscored the need for countries to build sovereign capacity in vaccine procurement and […]
Q&A Session
During the Q&A, Cambodia sought insights from Nepal on estimating out-of-school girls, who described combining education enrollment and census data adjusted at local government levels. Nepal also explained post-campaign monitoring using vaccination cards, rapid convenience surveys, and female community health volunteers for outreach. Bangladesh detailed its dual registration system (digital and manual) linked to birth […]
Regional overview: Cervical cancer epidemiology and HPV vaccination progress; Q&A Session
The Q&A session highlighted key implementation challenges and strategies for HPV vaccination in the Western Pacific and Southeast Asia regions. Questions focused on vaccine efficacy in older cohorts, strategies for multi-age campaigns, and the need to address zero-dose girls through improved catch-up initiatives. Country representatives, including Myanmar, Malaysia, and the Philippines, shared updates on data […]
Policy, Schedule and Vaccine Product Choice: Q&A Session
The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]
HPV vaccine cost and procurement: Q&A Session
The session’s discussion highlighted supply dynamics and market diversification for HPV vaccines, with UNICEF confirming five WHO-prequalified products currently available and several others in the pipeline, including a quadrivalent vaccine from SII. Participants raised questions on whether increased suppliers could reduce prices and how demand fluctuations after multi-age cohorts might affect costs. Indonesia and Lao […]